Physician profile
Thomas C Stuckey
NPI 1437177300
$5,719.51
in general payments reported to CMS, 2019-2025
23 companies · $1,560 in 2025
The $1,560 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $500 · 2021: $881 · 2022: $478 · 2023: $565 · 2024: $768 · 2025: $1,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,892.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,859.51 | 2019-2025 | Clareon, Rocklatan, Argos |
| Biotissue Holdings INC. | $672.45 | 2025 | |
| Allergan, INC. | $329.86 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $291.02 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $276.98 | 2019-2021 | |
| Rxsight INC | $266.43 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Johnson & Johnson Surgical Vision, INC. | $199.76 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Veritas Vision System |
| Bausch & Lomb Americas INC. | $163.06 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Glaukos Corporation | $111.51 | 2019-2023 | |
| Abbvie INC. | $110.03 | 2022-2025 | |
| Sight Sciences, INC. | $72.55 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Oyster Point Pharma, INC. | $58.89 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $50.16 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $43.40 | 2022-2023 | Dextenza |
| New World Medical,INC. | $38.46 | 2023-2025 | Clearpath, Via360, Streamline |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $32.09 | 2024 | Xdemvy |
| Dompe US, INC. | $28.46 | 2025 | Oxervate |
| Amgen INC. | $24.36 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $23.54 | 2019 | |
| Mallinckrodt Enterprises LLC | $21.82 | 2019 | |
| Eyepoint US, INC. | $15.81 | 2019 | |
| Sun Pharmaceutical Industries INC. | $15.58 | 2019 | |
| Ivantis, INC | $13.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Stuckey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.